Study introduces a novel approach to mapping protein-receptor interactions

One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells.

A rare disease first; Lilly’s Alzheimer’s push; Argenx’s next act; Novartis’ obesity approach; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 21, 2024

In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways

For years now, companies behind weight loss drugs like Wegovy and Zepbound have been trying to convince the medical community and the public that obesity

January 10, 2025

Social media channels could be harnessed to provide information about obesity to young people

There is an urgent need to harness the potential of TikTok and other social media channels to provide scientific information about obesity to young people

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.